Published online Jun 21, 2023. doi: 10.3748/wjg.v29.i23.3645
Peer-review started: February 9, 2023
First decision: March 9, 2023
Revised: March 16, 2023
Accepted: May 4, 2023
Article in press: May 4, 2023
Published online: June 21, 2023
Processing time: 127 Days and 1 Hours
The circadian clock gene NPAS2 expression is associated with multiple tumor prognosis, its role in gastric cancer (GC) is unknown.
NPAS2 can improve the accuracy of GC prognosis prediction and assist clinicians in postoperative patient management and decision-making.
This study aimed to explore the relationship between the circadian clock gene NPAS2 and the survival prognosis of GC patients and clarify its role in evaluating GC prognosis.
Immunohistochemical staining was used to detect the expression of NPAS2 protein in GC and adjacent tissues. Univariate and multivariate Cox regression analysis was used to determine the independent prognostic factors of GC, and a nomogram prediction model was established. The receiver operating characteristic curve and area under the curve, the calibration curve, and C-index were used to evaluate the predictive effectiveness of the model.
The NPAS2 expression were independent prognostic factors of overall survival in GC patients for 3 years.
NPAS2 is highly expressed in GC and is closely related to worse overall survival in patients. Therefore, the evaluation of NPAS2 expression may be a potential marker for GC prognosis evaluation.
Based on NPAS2 expression, clinicians can predict patient prognosis and guide clinical decision making and follow up.